Therapeutic targets in age-related macular disease

Journal of Clinical Investigation

Volumn 120, Issue 9, 2010, Pages 3033-3041

  Bird, Alan C ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

BRUCH MEMBRANE; CHOROID; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

AGING; ANGIOGENESIS INHIBITORS; ANIMALS; BLINDNESS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; EYE; HUMANS; MACULAR DEGENERATION; MICE; MICE, KNOCKOUT; RATS; RATS, SPRAGUE-DAWLEY; RESEARCH; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956378437     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42437     Document Type: Review

References (120)

1. Evans J. Studies on Medical and Population Subjects No 57. HMSO; 1995. Causes of blindness and partial sight in England and Wales 1990-1991.
2. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy. The Beaver-Dam Eye Study. Ophthalmology. 1992;99(6):933-943.
3. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology. 1995;102(10):1450-1460.
4. Vingerling JR, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995;102(2):205-210.
5. Hutchinson J, Tay W. Symmetrical central choriodol-retinal disease occurring in senile persons. R Lond Ophthalmic Rep. 1874;8:231-244.
6. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmol. 1996;80(1):9-14.
7. Gregor Z, Joffe L. Senile macular changes in the black African. Br J Ophthalmol. 1978;62(8):547-550.
8. Schachat AP, Hyman L, Leske MC, Connell AM, Wu SY. Features of age-related macular degeneration in a black population. Arch Ophthalmol. 1995;113(6):728-735.
9. Kubo N, Ohno Y, Yanagawa H, Yuzawa M, Matsui M, Uyama M. Annual estimated number of patients with senile disciform macular degeneration in Japan. Research committee on Chorioretinal Degenerations. The Ministry of Health and Welfare of Japan: Japan; 1989:136-139.
10. Kubo N, et al. Report on nationwide clinico-epidemiological survey of senile disciform macular degeneration in Japan. Research Committee on Chorioretinal Degenerations. The Ministry of Health and Welfare of Japan: Japan; 1990:121-124.
11. Yuzawa M, Hagita K, Egawa T, Minato H, Matsui M. Macular lesions predisposing to senile disciform macular degeneration. Jpn J Ophthalmol. 1991;35(1):87-95.
12. Maruo T, Ikebukuro N, Kawanabe K, Kubota N. Changes in causes of visual handicaps in Tokyo. Jpn J Ophthalmol. 1991;35(3):268-272.
13. Koh AH, Ang CL. Age-related macular degeneration: what's new. Ann Acad Med Singapore. 2002;31(3):399-404.
14. Yang CS, Lin CL, Lee FL, Tsai SC, Chung YM, Liu JH. Digital indocyanine green angiography in chorioretinal diseases. Chung Hua I Hsueh Tsa Chih Taipei. 1995;56(6):411-417.
15. Chen SN, Liu KR, Tsai CB, Yang CH, Yang CM, Chen MS. Indocyanine green videoangiography of choroidal neovascular membrane in age-related macular degeneration. J Formos Med Assoc. 1993;92(9):823-828.
16. Rosenberg T. Prevalence and causes of blindness in Greenland. Arctic Med Res. 1987;46(1):13-17.
17. Rosenberg T. Prevalence of blindness caused by senile macular degeneration in Greenland. Arctic Med Res. 1987;46(2):64-70.
18. Haines JL, et al. Complement factor H variant increases te risk of sge-related macular degeneration. Science. 2005;308(5720):419-421.
19. Klein RJ, et al. Complement factor H in age-related macular dgeneration. Science. 2005;308(5720):385-389.
20. Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA. Compliment factor H polymorphism and age-related macular dgeneration. Science. 2005;308(5720):421-424.
21. Hageman GS, et al. A common haplotype in the complimentary regulatory gene factor H (HF1/ CFH) predisposes individuals to age-related macular dgeneration. Proc Natl Acad Sci U S A. 2005;102(20):7227-7232.
22. Rivera A, et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005;14(21):3227-3236.
23. Fritsche LG, et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet. 2008;40(7):892-896.
24. Yates JR, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357(6):553-561.
25. Bergeron-Sawitzke J, et al. Multilocus analysis of age-related macular degeneration. Eur J Hum Genet. 2009;17(9):1190-1199.
26. Hageman GS, et al. AMD Clinical Study GroupExtended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med. 2006;38(8):592-604.
27. Leys A, Vanrenterghem Y, Van Damme B, Snyers B, Person Y, Leys M. Fundus changes in membranoprolipherative glomerulonephritis Type II: a fluorescein angiography study of 23 patients. Graefes Arch Clin Exp Ophthalmol. 1991;229(5):406-410.
28. de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355(14):1474-1485.
29. Chakravarthy U, et al. Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology. 2007;114(6):1157-1163.
30. Korte GE, Repucci V, Henkind P. RPE destruction causes choriocapilary atrophy. Invest Ophthalmol Vis Sci. 1984;25(10):1135-1145.
31. Blaauwgeers HG, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol. 1999;155(2):421-428.
32. Kannan R, et al. Stimulation of apical and basolateral VEGF-A and VEGF-C secretion by oxidative stress in polarized retinal pigment epithelial cells. Mol Vis. 2006;12:1649-1659.
33. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D'Amore PA. An essential role for RPEderived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A. 2009;106(44):18751-18756.
34. McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Lutty GA. Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50(10):4982-4991.
35. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PG, de Jong PT. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci. 1994;35(6):2857-2864.
36. Olver JM, McCartney AC. Orbital and ocular microvascular corrosion casting in man. Eye (Lond). 1989;3(pt 5):588-596.
37. Hogan MJ. Macular diseases, pathogenesis: Electron microscopy of Bruch's membrane. Trans Am Acad Ophthalmol Otolaryngol. 1965;69:683-690.
38. Green WR, Key SN. Senile macular degeneration: a histopathological study. Trans Am Ophthalmol Soc. 1977;75:180-250.
39. Sarks, S.H. Changes in the region of the choriocapillaris in aging and degeneration. 23rd Concilium Ophthalmol, Kyoto. 1978:228-238.
40. Tso MOM. Pathogenetic factors of aging macular degeneration. Ophthalmology. 1985;92(5):628-635.
41. Capon M, Marshall J, Krafft JI, Alexander RA, Hiscott PS, Bird AC. Sorsby's fundus dystrophy: A light and electron microscopic study. Ophthalmology. 1989;96(12):1769-1777.
42. Polkinghorne PJ, Capon MR, Berninger TA, Lyness AL, Sehmi K, Bird AC. Sorsby's fundus dystrophy: A clinical study. Ophthalmology. 1989;96(12):1763- 1768.
43. Meves H. Die pathologisch-anatomischen gefassveranderungen des Auges bei der beningen und malingen Nephrosklerose. Graefes Arch Ophthalmol. 1948;168:287.
44. Friedman E, Smith TR, Kuwabara T, Beyer CK. Choroidal vascular patterns in hypertension. Arch Ophthalmol. 1964;71:842-850.
45. Pauleikhoff D, Chen JC, Chisholm IH, Bird AC. Choroidal perfusion abnormalities in age related macular disease. Am J Ophthalmol. 1990;109(2):211-217.
46. Chen JC, Fitzke FW, Pauleikhoff D, Bird AC. Functional loss in age-related Bruch's membrane change with Choroidal Perfusion Defect. Invest Ophthalmol Vis Sci. 1992;33(2):334-340.
47. Steinmetz RL, Haimovici R, Jubb C, Fitzke FW, Bird AC. Symptomatic abnormalities of dark adaptation in patients with age-related Bruch's membrane change. Br J Ophthalmol. 1993;77(9):549-554.
48. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2000;130(5):658-663.
49. Green WR, Key SN. Senile macular degeneration: a histopathological study. Trans Am Ophthalmol Soc. 1977;75:180-254.
50. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PG, de Jong PT. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci. 1994;35(6):2857-2864.
51. Okubo A, et al. The relationships between age changes in retinal pigment epithelium and Bruch's membrane. Invest Ophthalmol Vis Sci. 1999;40(2):443-449.
52. Bird AC, Marshall J. Retinal pigment epithelial detachments in the elderly. Trans Ophthalmol Soc UK. 1986;105(pt 6):674-682.
53. Pauleikhoff D, Harper CA, Marshall J, Bird AC. Aging changes in Bruch's membrane: a histochemical and morphological study. Ophthalmology. 1990;97(2):171-178.
54. Holz FG, Sheraidah G, Pauleikhoff D, Bird AC. Analysis of lipid deposits extracted from macular and peripheral Bruch's membrane. Arch Ophthalmol. 1994;112(3):402-406.
55. Sheraidah G, Steinmetz R, Maguire J, Pauleikhoff D, Marshall J, Bird A. Correlation between lipids extracted from Bruch's membrane and age. Ophthalmology. 1993;100(1):47-51.
56. van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ. 2003;326(7383):255-256.
57. Li CM, et al. Lipoprotein-like particles and cholesteryl esters in human Bruch's membrane: initial characterization. Invest Ophthalmol Vis Sci. 2005;46(7):2576-2586.
58. Moore DJ, Hussain AA, Marshall J. Age related variation in the hydraulic conductivity of Bruch's membrane. Invest Ophthalmol Vis Sci. 1995;36(7):1290-1297.
59. Starita C, Hussain AA, Patmore A, Marshall J. Localization of the site of major resistance to fluid transport in Bruch's membrane. Invest Ophthalmol Vis Sci. 1997;38(3):762-767.
60. Pauleikhoff D, Zuels S, Sheraidah G, Marshall J, Wessing A, Bird AC. Correlation between biochemical composition and fluorescein binding of deposits in Bruch's membrane. Ophthalmology. 1992;99(10):1548-1553.
61. Chuang EL, Bird AC. Bilaterality of tears of the retinal pigment epithelium. Br J Ophthalmol. 1988;72(12):918-920.
62. Chuang EL, Bird AC. The pathogenesis of tears of the retinal pigment epithelium. Am J Ophthalmol. 1988;105(3):285-290.
63. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001;20(6):705-732.
64. Yoshida T, et al. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest. 2005;115(10):2793-2800.
65. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH. The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A. 2002;99(18):11830-11835.
66. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res. 2004;78(2):243-256.
67. Isas JM, et al. Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci. 2010;51(3):1304-1310.
68. Hageman GS, Mullins RF, Russell SR, Johnson LV, Anderson DH. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. FASEB J. 1999;13(3):477-484.
69. Wasmuth S, Lueck K, Baehler H, Lommatzsch A, Pauleikhoff D. Increased vitronectin production by complement-stimulated human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 2009;50(11):5304-5309.
70. Anderson DH, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res. 2010;29(2):95-112.
71. Nan R, Gor J, Lengyel I, Perkins SJ. Uncontrolled zinc- and copper-induced oligomerisation of the human complement regulator factor H and its possible implications for function and disease. J Mol Biol. 2008;384(5):1341-1352.
72. Lengyel I, et al. High concentration of zinc in subretinal pigment epithelial deposits. Exp Eye Res. 2007;84(4):772-780.
73. Li W, Chen S, Ma M, Qian J, Ma X. Complement 5b-9 complex-induced alterations in human RPE cell physiology. Med Sci Monit. 2010;16(1):BR17-BR23.
74. Hollyfield JG. Age-related macular degeneration: the molecular link between oxidative damage, tissue-specific inflammation and outer retinal disease: the Proctor lecture. Invest Ophthalmol Vis Sci. 2010;51(3):1275-1281.
75. Coffey PJ, et al. Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. Proc Natl Acad Sci U S A. 2007;104(42):16651-16656.
76. Lovell MA. A potential role for alterations of zinc and zinc transport proteins in the progression of Alzheimer's disease. J Alzheimers Dis. 2009;16(3):471-483.
77. Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1996;37(7):1236-1249.
78. Katz ML, Norberg M. Influence of dietary vitamin A on autofluorescence of leupeptin-induced inclusions in the retinal pigment epithelium. Exp Eye Res. 1992;54(2):239-246.
79. Steinmetz RL, McGuire J, Garner A, Bird AC. Histopathology of incipient fundus flavimaculatus. Ophthalmology. 1991;98(6):953-956.
80. Weng J, Travis GH. Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. Proc Natl Acad Sci U S A. 2000;97(13):7154-7159.
81. Jonasson F, Arnarsson A, Sasaki H, Peto T, Sasaki K, Bird AC. The prevalence of age-related maculopathy in Iceland: Reykjavik eye study. Arch Ophthalmol. 2003;121(3):379-385.
82. Björnsson OM, Syrdalen P, Bird AC, Peto T, Kinge B. The prevalence of age-related maculopathy (ARM) in an urban Norwegian population: the Oslo Macular study. Acta Ophthalmol Scand. 2006;84(5):636-641.
83. von Rückmann A, Fitzke FW, Bird AC. Distribution of fundus autofluorescence with a scanning laser ophthalmoscope. Br J Ophthalmol. 1995;79(5):407-412.
84. Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelial lipofuscin characteristics. Invest Ophthalmol Vis Sci. 1995;36(3):718-729.
85. Lois N, Coco R, Hopkins J, Owens SL, Fitzke FW, Bird AC. Fundus autofluorescence in patients with age-related macular degeneration and high risk characteristics. Am J Ophthalmol. 2002;133(3):341-349.
86. Holz FG, Bellman C, Staudt S, Schutt F, Volcker HE. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2001;42(5):1051-1056.
87. Feeney-Burns L, Eldred GE. The fate of the phagosome: conversion to "age-pigment" and impact in human retinal pigment epithelium. Trans Ophthalmol Soc UK. 1984;103(pt 4):416-421.
88. Rozanowska M, et al. Photoreactivity of aged human RPE melanosomes: a comparison with lipofuscin. Invest Ophthalmol Vis Sci. 2002;43(7):2088-2096.
89. Holz FG, et al. Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci. 1999;40(3):737-743.
90. Schutt F, Bergmann M, Holz FG, Kopitz J. Isolation of intact lysosomes from human RPE cells and effects of A2-E on the integrity of the lysosomal and other cellular membranes. Graefes Arch Clin Exp Ophthalmol. 2002;240(12):983- 988.
91. Lakkaraju A, Finnemann SC, Rodriguez-Boulan E. The lipofuscin fluorophore A2E perturbs cholesterol metabolism in retinal pigment epithelial cells. Proc Natl Acad Sci U S A. 2007;104(26):11026-11031.
92. Okubo A, Sameshima M, Unoki K, Uehara F, Bird AC. Ultrastructural changes associated with accumulation of inclusion bodies in rat retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2000;41(13):4305-4312.
93. Wiegand RD, Koutz CA, Stinson AM, Anderson RE. Conservation of docosahexaenoic acid in rod outer segments of rat retina during n-3 and n-6 fatty acid deficiency. J Neurochem. 1991;57(5):1690-1699.
94. Stinson AM, Wiegand RD, Anderson RE. Recycling of docosahexaenoic acid in rat retinas during n-3 fatty acid deficiency. J Lipid Res. 1991;32(12): 2009-2017.
95. Zhou J, Kim SR, Westlund BS, Sparrow JR. Complement activation by bisretinoid constituents of RPE lipofuscin. Invest Ophthalmol Vis Sci. 2009;50(3):1392-1399.
96. Scholl HPN, Bellmann C, Dandekar SS, Bird AC, Fitzke FW. Photopic and scotopic fine matix mapping of retinal areas of increased fundus autofluorescence in patients with age related macular degeneration. Invest Ophthalmol Vis Sci. 2004;45(2):574-583.
97. Radu RA, Mata NL, Nusinowitz S, Liu X, Sieving PA, Travis GH. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci U S A. 2003;100(8):4742-4747.
98. Hogan MJ. Role of the retinal pigment epithelium in macular disease. Trans Am Acad Ophthalmol Otolaryngol. 1972;76(1):64-80.
99. Sarks SH. Ageing and degeneration in the macular region: a clinico-pathological study. Br J Ophthalmol. 1976;60(5):324-341.
100. Wolf-Schnurrbusch UEK, Enzmann V, Brinkmann CK, Wolf S. Morphological changes in patients with geographic atrophy assessed with a novel spectral OCT-SLO combination. Invest Ophthalmol Vis Sci. 2008;49(7):3095-3099.
101. Fleckenstein M, et al. High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008;49(9):4137-4144.
102. Kim YH, He S, Kase S, Kitamura M, Ryan SJ, Hinton DR. Regulated secretion of complement factor H by RPE and its role in RPE migration. Graefes Arch Clin Exp Ophthalmol. 2009;247(5):651-659.
103. Fu QL, et al. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience. 2009;162(2):375-382.
104. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22(1):1-29.
105. Maminishkis A, et al. Confluent monolayers of cultured human fetal retinal pigment epithelium exhibit morphology and physiology of native tissue. Invest Ophthalmol Vis Sci. 2006;47(8):3612-3624.
106. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37(9):1929-1934.
107. Bhutto IA, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res. 2006;82(1):99-110.
108. Miller H, Miller B, Ishibashi T, Ryan SJ. Pathogenesis of laser-induced choroidal subretinal neovascularization. Invest Ophthalmol Vis Sci. 1990;31(5):899-908.
109. Renno RZ, Youssri AI, Michaud N, Gragoudas ES, Miller JW. Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2002;43(5):1574-1580.
110. Wada M, Ogata N, Otsuji T, Uyama M. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr Eye Res. 1999;18(3):203-213.
111. Yamagishi K, Ohkuma H, Itagaki T, Katoh N, Takahashi K, Uyama M. Implication of retinal pigment epithelium on experimental subretinal neovascularization in the developmental stage. Nippon Ganka Gakkai Zasshi. 1988;92(10):1629-1636.
112. Yannuzzi LA, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21(5):416-434.
113. Kaiser PK, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144(6):850-857.
114. Boyer DS, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246-252.
115. Miller JW, et al. Vascular endothelial growth factor/ vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145(3):574-584.
116. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92(3):905-909.
117. Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res. 2007;85(6):762-771.
118. Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146(4):496-500.
119. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000;45(2):115-134.
120. Brennan LA, Kantorow M. Mitochondrial function and redox control in the aging eye: role of MsrA and other repair systems in cataract and macular degenerations. Exp Eye Res. 2009;88(2):195-203.